NCT03335280 is a clinical trial of 68Ga-citrate PET/MR in Glioma, sponsored by Susan Chang.

Who is sponsoring NCT03335280?

NCT03335280 is sponsored by Susan Chang.

What drugs are being tested in NCT03335280?

Interventions in NCT03335280: 68Ga-citrate PET/MR.

Is NCT03335280 still recruiting?

NCT03335280 is currently terminated. Last updated 1 May 2020.

Last reviewed 2020-05-01 · How we verify

NCT03335280

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

68Ga-citrate PET/MR Imaging for Glioma

Terminated Last updated 1 May 2020

What this trial tests

trial testing 68Ga-citrate PET/MR in Glioma in 2 participants. Terminated before completion.

Timeline

26 February 2019

Primary endpoint
24 April 2020

24 April 2020

Quick facts

Lead sponsor	Susan Chang
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	2
Start date	26 February 2019
Primary completion	24 April 2020
Estimated completion	24 April 2020
Sites	1 location across United States

Drugs / interventions tested

68Ga-citrate PET/MR — full drug profile →

Conditions studied

Glioma — all drugs for Glioma →

Sponsor

Susan Chang — full company profile →

Who can join

Adults 18 to 85, any sex, with Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate Positron Emission Tomography / magnetic resonance (PET/MR) prior to surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Glioma

Currently open trials in the same condition.

NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
NCT07236840 — Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors · recruiting
NCT07450872 — Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors · recruiting
NCT07405372 — Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas · recruiting
NCT07338539 — BIO-SHORT: Biologically Guided Short-Course Hypofractionated RT for Poor-Prognosis GBM · Phase 2 · recruiting

Other Susan Chang trials

Trials by the same sponsor.

NCT04019002 — Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma · Phase 1 · completed
NCT04540107 — Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma · Phase 1 · recruiting
NCT03739411 — Hyperpolarized Imaging in Diagnosing Participants With Glioma · Phase 1 · recruiting
NCT00823459 — Everolimus in Treating Patients With Recurrent Low-Grade Glioma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03335280 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Susan Chang
Last refreshed: 1 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03335280.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing